New York, February 2, 2026, 12:48 EST — Regular session
- Shares edged higher midday following reports that a Massachusetts facility is winding down
- Planned layoffs were reduced to 80, down from 103 initially reported in a state notice
- After last week’s cautious 2026 outlook, investors are zeroing in on cost measures and demand indicators
Thermo Fisher Scientific shares climbed roughly 0.7% to $582.94 in midday Monday trading. The company plans to wind down operations at its Franklin, Massachusetts facility by the end of 2026, cutting as many as 80 jobs, according to a state notice and a company spokesperson cited by Fierce Pharma. During the session, the stock fluctuated between $573.32 and $583.69.
The Franklin shift highlights how life-sciences suppliers keep adjusting their footprints amid uneven customer spending. A statement shared by CBS Boston noted that “decisions that impact colleagues are never taken lightly.” Meanwhile, local reports referenced the Boston Business Journal, pointing to funding slowdowns and policy changes stirring uncertainty among some customers. CBS News
Last week, Thermo Fisher projected adjusted earnings per share for 2026 between $24.22 and $24.80, falling short of analysts’ midpoint estimates. The company expects revenue in the range of $46.3 billion to $47.2 billion. CEO Marc Casper indicated to analysts that the company is planning for steady conditions among academic and government clients, despite cuts and freezes in U.S. research funding. Thermo Fisher also noted that completing its up to $9.4 billion acquisition of Clario by mid-2026 could boost adjusted EPS by 20 to 25 cents.
Thermo Fisher informed state officials in a Jan. 23 letter that it planned to lay off 103 of about 200 workers at its Franklin facility, with most cuts set for Dec. 31. The company later trimmed that number to 80, spokesperson Jodie Wertheim told The Boston Globe. She added that work would be moved to other U.S. plants as the Franklin site winds down by the end of 2026. According to the paper, the plant primarily produces air quality monitors, industrial hygiene instruments, and flow computers.
Layoffs this large typically come with a WARN notice, named after the Worker Adjustment and Retraining Notification Act. Federal rules require companies with 100 or more employees to give at least 60 days’ warning before a plant shutdown or major layoff, barring certain exceptions.
Thermo Fisher reported in its Jan. 29 earnings release that fourth-quarter revenue climbed 7% to $12.21 billion, with adjusted earnings hitting $6.57 per share. Casper noted the company started 2026 from a “position of strength,” following a year marked by capital deployment and capability expansion. Thermo Fisher Scientific
Investors are keeping an eye on whether these site moves cut costs without slowing deliveries, and how much restructuring hit shows up in the next quarters. The bigger issue remains demand: academic, government, and biotech clients can shift rapidly from cautious to busy—or stay restrained far longer than management expects.
The downside risk is still in play. Should research funding stay tight or customers push back projects once more, Thermo Fisher could face pressure to take further measures — more transfers, additional closures — which would weigh on margins and keep the stock volatile.
Thermo Fisher is set to attend SLAS 2026 in Boston from Feb. 7–11 at the Thomas Michael Menino Convention & Exhibition Center, offering a stage for new product or workflow announcements. Yet, investors will probably focus more on demand updates and any hints of restructuring as February’s trading takes shape.
